Issues related to sex differences in antipsychotic treatment

Current Opinion in Psychiatry

Volumn 29, Issue 3, 2016, Pages 211-217

  Crawford, Mitchell B ^a   DeLisi, Lynn E ^b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antipsychotic; gender; menopause; pregnancy; sex; women

Indexed keywords

NEUROLEPTIC AGENT;

ACNE; BREAST FEEDING; CATARACT; DOSE RESPONSE; DRUG EFFICACY; HORMONE SYNTHESIS; HUMAN; MENOPAUSE; META ANALYSIS (TOPIC); METABOLIC DISORDER; NONHUMAN; POSTMENOPAUSE; PREGNANCY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; DRUG EFFECTS; FEMALE; MALE; PROSPECTIVE STUDY; SCHIZOPHRENIA; SEXUAL BEHAVIOR; SEXUAL DEVELOPMENT;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PREGNANCY; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX CHARACTERISTICS; SEX FACTORS; SEXUAL BEHAVIOR;

EID: 84959118082     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000243     Document Type: Review

References (50)

1. SeemanM.Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161:1324-1333.
2. Seeman M. Women and psychosis. Womens Health 2012; 8:215-224.
3. Greenblatt DJ, Harmatz JS, Singh NN, et al. Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol 2014; 54:282-290.
4. Prendergast B, Onishi K, Zucker I. Female mice liberated for inclusion in neuroscience and biomedical research. Neurosci Biobehav Rev 2014; 40:1-5. The review discusses that the variability between male and female mice was not statistically significant for the variables that were studied.
5. Bangasser DA, Valentino RJ. Sex differences in stress-related psychiatric disorders: Neurobiological perspectives. Front Neuroendocrinol 2014; 35:303-319.
6. Tabatadze N,Huang G, MayRM1, et al. Sex differences in molecular signaling at inhibitory synapses in the hippocampus. J Neurosci 2015; 35:11252-11265.
7. Chaves A, Seeman M. Sex selection bias in schizophrenia antipsychotic trials. J Clin Psychopharmacol 2006; 26:489-494.
8. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature 2014; 509:282-283.
9. Sandberg K, Umans JG; Georgetown Consensus Conference Work Group. Recommendations concerning the new U.S. National Institutes of Health initiative to balance the sex of cells and animals in preclinical research. FASEB J 2015; 29:1646-1652.
10. Rabinowitz J, Werbeloff N, Caers I, et al. Determinants of antipsychotic response in schizophrenia: Implications for practice and future clinical trials. J Clin Psychiatry 2014; 75:e308-e316. The analysis of data from multiple randomized control trials showed a difference in response to antipsychotics between the sexes.
11. Melkersson K, Hulting A, Rane A. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. J Clin Pharmacol 2000; 51:317-324.
12. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: A randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry 2015; 76:554-561.
13. Subotnik K, Casaus L, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. JAMA Psychiatry 2015; 72:822-829.
14. ZYPREXA1 Olanzapine Tablets, ZYPREXA1 ZYDIS1 Olanzapine Orally Disintegrating Tablets, ZYPREXA1 IntraMuscular Olanzapine for Injection [Internet]. FDA Docket: Eli Lilly and Company; 1997 [updated 2008, August 14; cited 2015, December 15]. Available from: Http://www.accessdata.fda.- gov/drugsatfda-docs/label/2004/20592se1-019-zyprexa-lbl.pdf
15. Walther S, Moggi F, Horn H, et al. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: A naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. J Clin Psychopharmacol 2014; 34:124-128.
16. Ranney M, Locci N, Adams E, et al. Gender-specific research on mental illness in the emergency department: Current knowledge and future directions. Acad Emerg Med 2014; 21:1395-1402.
17. Seeman M. Secondary effects of antipsychotics: Women at greater risk than men. Schizophr Bull 2009; 35:937-948.
18. Seeman M. Antipsychotics and physical attractiveness. Clin Schizophr Relat Psychoses 2011; 5:142-146.
19. Pé rez-Iglesias R, Ortiz-Garcia De La Foz V, Martínez García O, et al. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophr Res 2014; 159:90-94.
20. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159:133-135.
21. Seeman M. Antipsychotic-induced amenorrhea. J Ment Health 2011; 20:484-491.
22. Seeman M, Ross R. Prescribing contraceptives for women with schizophrenia. J Psychiatr Pract 2011; 17:258-269.
23. Einarson A, Boskavic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183.
24. Miotto P, Pollini B, Restaneo A, et al. Symptoms of psychosis in anorexia and bulimia nervosa. Psychiatry Res 2010; 175:237-243.
25. Seeman M. Eating disorders and psychosis: Seven hypotheses. World J Psychiatry 2014; 4:112-119.
26. Bale TL, Epperson CN. Sex differences and stress across the lifespan. Nat Neurosci 2015; 18:1413-1420.
27. Kulkarni J, Storch A, Baraniuk A, et al. Antipsychotic use in pregnancy. Expert Opin Pharmacother 2015; 16:1335-1345.
28. Toh S, Li Q, Cheetham T, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: A population-based study of 585,615 deliveries. Arch Womens Ment Health 2013; 16:149-157.
29. Altshuler L, Cohen L, Szuba M, et al. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry 1996; 153:592.
30. Cohen L, Viguera A, McInerney K, et al. Establishment of the National Pregnancy Registry for Atypical Antipsychotics. J Clin Psychiatry 2015; 76:986-989.
31. Menon S. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet 2008; 277:1-13.
32. Kennedy D. Antipsychotic drugs in pregnancy and breastfeeding. Aust Prescr 2007; 30:162-163.
33. Diav-Citron O, Scechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: A multicenter, prospective controlled study. J Clin Psychiatry 2005; 66:317.
34. Slone D, Siskind V, Heinonen O, et al. Antenatal exposure to the phonothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977; 128:486.
35. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparison study. J Clin Psychiatry 2005; 66:444.
36. Habermann F, Fritzsche J, Fuhlbruck F, et al. Atypical antipsychotic drugs and pregnancy outcomes: A prospective, cohort study. J Clin Psychopharmacol 2013; 33:453-462.
37. Newham J, Thomas S, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: Prospective comparison study. Br J Psychiatry 2008; 192:333.
38. Coughlin C, Blackwell K, Bartley C, et al. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol 2015; 125:1224-1235.
39. Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: A cohort study. BMJ Open 2013; 3:pii: E003062. doi: 10.1136/bmjopen-2013-003062.
40. Gentile S. Antipsychotic therapy during early and late pregnancy: A systematic review. Schizophr Bull 2010; 36:518-544.
41. Johnson K, LaPrairie J, Brennan P, et al. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry 2012; 69:787.
42. Gentile S. Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety 2010; 27:675.
43. Seeman M. Estrogen, schizophrenia and neurodevelopment. Womens Health 2006; 2:571-576.
44. Newport D, Calamaras M, DeVane C, et al. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164:1214.
45. Seeman M. Pseudocyesis delusional pregnancy, and psychosis: The birth of a delusion. World J Clin Cases 2014; 2:338-344.
46. Seeman M, Gupta R. Selective review of age-related needs of women with schizophrenia. Clin Schizophr Relat Psychoses 2015; 9:21-29.
47. Grigoriadis S, Seeman M. The role of estrogen in schizophrenia: Implications for schizophrenia practice guidelines for women. Can J Psychiatry 2002; 47:437-442.
48. Heringa SM, Begemann MJ, Goverde AJ, Sommer IE. Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review. Schizophr Res 2015; 168:603-613.
49. Tharoor H,Goyal A. Raloxifene trial in postmenopausal woman with treatmentresistant schizophrenia. Arch Womens Ment Health 2015; 18:741-742.
50. Wong J, Seeman M, Shapiro H. Case report: Raloxifene in postmenopausal women with psychosis: Preliminary findings. Am J Geriatr Psychiatry 2003; 11:697-698.